<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00754000</url>
  </required_header>
  <id_info>
    <org_study_id>CMT-03-08</org_study_id>
    <nct_id>NCT00754000</nct_id>
  </id_info>
  <brief_title>The AIM Study: Assessing the Impact of Margin Reduction</brief_title>
  <acronym>AIM</acronym>
  <official_title>The AIM Study: Assessing the Impact of Margin Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Varian Medical</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Varian Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will observe patients who receive external beam radiation for prostate cancer.
      These patients will be localized and tracked (targeted) with the Calypso 4D Localization
      System. These patients will have a uniform treatment plan with reduced PTVs (prostate
      treatment volume) and will be assessed at multiple time points for quality of life and side
      effects related to radiation therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      EPIC surveys and adverse events recorded and categorized using the CTCAE v3.0 will be
      collected and summary statistics performed. The patient's individual tracking graphs will be
      evaluated for motion type and frequency.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate patient quality of life using Expanded Prostate Cancer Index Composite (EPIC) for evaluation of the QOL</measure>
    <time_frame>2 year follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collection of patient tracking data from the Calypso 4D Localization System</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Record the number of interventions patients receive during radiation delivery to maintain the target within the treatment plan</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the user satisfaction with the Calypso 4D Localization System</measure>
    <time_frame>At time of use</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate acute and chronic (up to 2 years) toxicities of external beam prostate radiation using Common Terminology Criteria for Adverse Events for standardization of acute and chronic toxicities from the subject</measure>
    <time_frame>2 year follow-up</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">82</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>All patients in study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>AE monitoring and EPIC QOL survey</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>EPIC survey</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Males diagnosed with prostate cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who are planning to receive external beam radiation of prostate

          2. Patients who are to be implanted with Beacon Transponders in the prostate

          3. 18 years of age or older.

          4. Histologically confirmed diagnosis of prostate cancer.

          5. Ability to comply with study visit schedule.

          6. Signed informed consent form.

        Exclusion Criteria:

          1. Any patients who have received other investigational therapy within the last 60 days
             are excluded.

          2. Individuals that have previously been implanted with permanent Beacon transponders are
             excluded.

          3. Patients that have any prosthetic implants in the pelvic region that contain metal or
             conductive materials (e.g., an artificial hip).

          4. Any other medical or other condition that would, at the discretion of the
             investigator, preclude the individual from participation in a clinical study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Constantine Mantz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>21st Century Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>21st Century Oncology - Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology - Santa Monica</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology</name>
      <address>
        <city>Cape Coral</city>
        <state>Florida</state>
        <zip>33990</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology - Plantation</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pollack A. &quot;The Prostate&quot; in Radiation Oncology: Rationale, Techniques and Results edited by Cox and Ang. Mosby 2003 p 630.</citation>
  </reference>
  <reference>
    <citation>Hanks GE, Leibel SA, Krall JM, Kramer S. Patterns of care studies: dose-response observations for local control of adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1985 Jan;11(1):153-7.</citation>
    <PMID>3967982</PMID>
  </reference>
  <reference>
    <citation>Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1111-6.</citation>
    <PMID>12128109</PMID>
  </reference>
  <reference>
    <citation>Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, Shipley WU. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005 Sep 14;294(10):1233-9. Erratum in: JAMA. 2008 Feb 27;299(8):899-900.</citation>
    <PMID>16160131</PMID>
  </reference>
  <reference>
    <citation>Chandra A, Dong L, Huang E, Kuban DA, O'Neill L, Rosen I, Pollack A. Experience of ultrasound-based daily prostate localization. Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):436-47.</citation>
    <PMID>12738318</PMID>
  </reference>
  <reference>
    <citation>Michalski JM, Purdy JA, Winter K, Roach M 3rd, Vijayakumar S, Sandler HM, Markoe AM, Ritter MA, Russell KJ, Sailer S, Harms WB, Perez CA, Wilder RB, Hanks GE, Cox JD. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):391-402.</citation>
    <PMID>10661346</PMID>
  </reference>
  <reference>
    <citation>Rudat V, Schraube P, Oetzel D, Zierhut D, Flentje M, Wannenmacher M. Combined error of patient positioning variability and prostate motion uncertainty in 3D conformal radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys. 1996 Jul 15;35(5):1027-34.</citation>
    <PMID>8751412</PMID>
  </reference>
  <reference>
    <citation>Antolak JA, Rosen II, Childress CH, Zagars GK, Pollack A. Prostate target volume variations during a course of radiotherapy. Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):661-72.</citation>
    <PMID>9806528</PMID>
  </reference>
  <reference>
    <citation>Little DJ, Dong L, Levy LB, Chandra A, Kuban DA. Use of portal images and BAT ultrasonography to measure setup error and organ motion for prostate IMRT: implications for treatment margins. Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1218-24.</citation>
    <PMID>12873664</PMID>
  </reference>
  <reference>
    <citation>Smitsmans MH, de Bois J, Sonke JJ, Betgen A, Zijp LJ, Jaffray DA, Lebesque JV, van Herk M. Automatic prostate localization on cone-beam CT scans for high precision image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):975-84.</citation>
    <PMID>16253772</PMID>
  </reference>
  <reference>
    <citation>Litzenberg DW, Balter JM, Hadley SW, Sandler HM, Willoughby TR, Kupelian PA, Levine L. Influence of intrafraction motion on margins for prostate radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):548-53. Epub 2006 Mar 20.</citation>
    <PMID>16545919</PMID>
  </reference>
  <reference>
    <citation>Balter JM, Wright JN, Newell LJ, Friemel B, Dimmer S, Cheng Y, Wong J, Vertatschitsch E, Mate TP. Accuracy of a wireless localization system for radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):933-7.</citation>
    <PMID>15708277</PMID>
  </reference>
  <reference>
    <citation>Litzenberg DW, Willoughby TR, Balter JM, Sandler HM, Wei J, Kupelian PA, Cunningham AA, Bock A, Aubin M, Roach M 3rd, Shinohara K, Pouliot J. Positional stability of electromagnetic transponders used for prostate localization and continuous, real-time tracking. Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1199-206. Epub 2007 May 21.</citation>
    <PMID>17513060</PMID>
  </reference>
  <reference>
    <citation>Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003 Jul;13(3):176-81. Review.</citation>
    <PMID>12903007</PMID>
  </reference>
  <reference>
    <citation>Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000 Dec 20;56(6):899-905.</citation>
    <PMID>11113727</PMID>
  </reference>
  <reference>
    <citation>Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008 Mar 20;358(12):1250-61. doi: 10.1056/NEJMoa074311.</citation>
    <PMID>18354103</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2008</study_first_submitted>
  <study_first_submitted_qc>September 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2008</study_first_posted>
  <last_update_submitted>April 27, 2012</last_update_submitted>
  <last_update_submitted_qc>April 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <pending_results>
    <submitted>July 20, 2015</submitted>
    <returned>August 17, 2015</returned>
    <submitted>October 13, 2015</submitted>
    <returned>November 13, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

